KR20220151643A - 바이러스 감염에 사용하기 위한 화합물 - Google Patents

바이러스 감염에 사용하기 위한 화합물 Download PDF

Info

Publication number
KR20220151643A
KR20220151643A KR1020227034317A KR20227034317A KR20220151643A KR 20220151643 A KR20220151643 A KR 20220151643A KR 1020227034317 A KR1020227034317 A KR 1020227034317A KR 20227034317 A KR20227034317 A KR 20227034317A KR 20220151643 A KR20220151643 A KR 20220151643A
Authority
KR
South Korea
Prior art keywords
day
compound
substituted
unsubstituted
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227034317A
Other languages
English (en)
Korean (ko)
Inventor
마린 파블로 아빌레스
곤잘레스 알레한드로 로사다
소사-파로 호세 마리아 페르난데즈
무뇨스 살바도르 푸디오
Original Assignee
파르마 마르, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마 마르, 에스.에이. filed Critical 파르마 마르, 에스.에이.
Publication of KR20220151643A publication Critical patent/KR20220151643A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227034317A 2020-03-02 2021-03-02 바이러스 감염에 사용하기 위한 화합물 Pending KR20220151643A (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
EP20382152.5 2020-03-02
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382192.1 2020-03-13
EP20382266 2020-04-02
EP20382266.3 2020-04-02
EP20382339 2020-04-27
EP20382339.8 2020-04-27
EP20382816.5 2020-09-16
EP20382816 2020-09-16
EP20382815.7 2020-09-16
EP20382815 2020-09-16
EP21382059 2021-01-25
EP21382059.0 2021-01-25
PCT/EP2021/055147 WO2021175831A2 (en) 2020-03-02 2021-03-02 Compounds for use in viral infections

Publications (1)

Publication Number Publication Date
KR20220151643A true KR20220151643A (ko) 2022-11-15

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227034317A Pending KR20220151643A (ko) 2020-03-02 2021-03-02 바이러스 감염에 사용하기 위한 화합물
KR1020227034280A Pending KR20220150350A (ko) 2020-03-02 2021-03-02 염증성 질환에 사용하기 위한 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227034280A Pending KR20220150350A (ko) 2020-03-02 2021-03-02 염증성 질환에 사용하기 위한 화합물

Country Status (17)

Country Link
US (2) US20230159594A1 (https=)
EP (2) EP4114433A2 (https=)
JP (2) JP2023517536A (https=)
KR (2) KR20220151643A (https=)
CN (2) CN115461067A (https=)
AU (2) AU2021232535A1 (https=)
BR (2) BR112022016604A2 (https=)
CA (2) CA3169540A1 (https=)
CL (2) CL2022002396A1 (https=)
CO (2) CO2022014093A2 (https=)
IL (2) IL296069A (https=)
MX (2) MX2022010926A (https=)
PE (2) PE20230606A1 (https=)
PY (2) PY2117301A (https=)
TW (2) TWI908772B (https=)
UY (2) UY39109A (https=)
WO (2) WO2021175831A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158102A1 (en) * 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in the treatment of coronavirus infection
CN115461067A (zh) * 2020-03-02 2022-12-09 法马马有限公司 用于炎症的化合物
AU2021231521A1 (en) * 2020-03-02 2022-10-06 Pharma Mar, S.A. PLD for use in combination in the treatment of coronavirus
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
WO1999052515A2 (de) * 1998-04-14 1999-10-21 Hassan Jomaa Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
DK1347743T3 (da) * 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Præparat til behandling af inflammatoriske lidelser
EP1596823A2 (en) * 2003-02-21 2005-11-23 Sun Pharmaceuticals Industries Ltd. A stable ophthalmic composition
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
BR112012014624A8 (pt) * 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CN115461067A (zh) * 2020-03-02 2022-12-09 法马马有限公司 用于炎症的化合物

Also Published As

Publication number Publication date
WO2021175857A1 (en) 2021-09-10
JP2023517536A (ja) 2023-04-26
IL296068A (en) 2022-11-01
PE20230412A1 (es) 2023-03-07
PY2117301A (es) 2022-08-09
PY2117308A (es) 2022-08-09
TWI908772B (zh) 2025-12-21
TW202144381A (zh) 2021-12-01
CN115461067A (zh) 2022-12-09
KR20220150350A (ko) 2022-11-10
JP2023517535A (ja) 2023-04-26
UY39109A (es) 2021-09-30
CA3169540A1 (en) 2021-09-10
US20230159594A1 (en) 2023-05-25
UY39110A (es) 2021-09-30
AU2021232535A1 (en) 2022-10-06
CL2022002395A1 (es) 2023-06-30
BR112022016604A2 (pt) 2022-10-11
MX2022010921A (es) 2022-09-29
AU2021231197A1 (en) 2022-10-06
EP4114435A1 (en) 2023-01-11
IL296069A (en) 2022-11-01
CO2022014093A2 (es) 2022-11-18
TW202146038A (zh) 2021-12-16
EP4114433A2 (en) 2023-01-11
US20230295236A1 (en) 2023-09-21
WO2021175831A3 (en) 2021-10-14
PE20230606A1 (es) 2023-04-10
CA3169544A1 (en) 2021-09-10
WO2021175831A2 (en) 2021-09-10
CN115666616A (zh) 2023-01-31
CL2022002396A1 (es) 2023-06-30
CO2022014031A2 (es) 2022-10-21
MX2022010926A (es) 2022-09-29
BR112022016675A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
KR20220151643A (ko) 바이러스 감염에 사용하기 위한 화합물
TWI844786B (zh) 一種藥物組合物及其應用
JP2021046436A (ja) ペプチド模倣大環状分子およびその製剤
CN115484953A (zh) 治疗细胞因子风暴综合症及相关疾病的方法
CN111867582A (zh) 衣壳组装调节剂给药方案
JP2019529477A (ja) 非アルコール性脂肪肝疾患治療のための医薬組成物および方法
US20220370384A1 (en) Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
KR20220151181A (ko) 코로나바이러스 감염의 치료에 사용하기 위한 화합물
AU2013240456A1 (en) Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
JP4683844B2 (ja) インフルエンザウイルス感染予防剤
KR100930480B1 (ko) 신규 디아릴 헵타노이드계 화합물 및 그 용도
JP2023517537A (ja) 自己免疫状態に使用するための化合物
CN117838689A (zh) 培菲替尼在制备治疗流感病毒感染的药物中的应用
WO2024165764A1 (en) Plitidepsin for use in the treatment of non-integrated dna viral infections
KR20250002212A (ko) 인플루엔자 및 폭스바이러스 바이러스 감염을 치료하는 방법
KR100931249B1 (ko) 신규 디아릴 헵타노이드계 화합물 및 그 용도
WO2021202745A1 (en) Treatment of covid-19 with a sine compound
HK40063844B (zh) 一种药物组合物及其应用
CN114377015A (zh) 萘哌地尔在制备抗流感病毒药物中的应用
HK1104460A1 (en) Use for the manufacture of a medicament for treatment or prophylaxis of infectious diseases
HK1104460B (en) Use for the manufacture of a medicament for treatment or prophylaxis of infectious diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application